WT1 immunoreactivity in breast carcinoma: Selective expression in pure and mixed mucinous subtypes

Akosua B. Domfeh, Annamarie L. Carley, Joan M. Striebel, Rouzan G. Karabakhtsian, Anca V. Florea, Kim McManus, Sushil Beriwal, Rohit Bhargava

Research output: Contribution to journalArticlepeer-review

62 Scopus citations


Current literature suggests that strong WT1 expression in a carcinoma of unknown origin virtually excludes a breast primary. Our previous pilot study on WT1 expression in breast carcinomas has shown WT1 expression in approximately 10% of carcinomas that show mixed micropapillary and mucinous morphology (Mod Pathol 2007;20(Suppl 2):38A). To definitively assess as to what subtype of breast carcinoma might express WT1 protein, we examined 153 cases of invasive breast carcinomas. These consisted of 63 consecutive carcinomas (contained 1 mucinous tumor), 20 cases with micropapillary morphology (12 pure and 8 mixed), 6 micropapillary 'mimics' (ductal no special type carcinomas with retraction artifacts), 33 pure mucinous carcinomas and 31 mixed mucinous carcinomas (mucinous mixed with other morphologic types). Overall, WT1 expression was identified in 33 carcinomas, that is, 22 of 34 (65%) pure mucinous carcinomas and in 11 of 33 (33%) mixed mucinous carcinomas. The non-mucinous component in these 11 mixed mucinous carcinomas was either a ductal no special type carcinoma (8 cases) or a micropapillary component (3 cases). WT1 expression level was similar in both the mucinous and the non-mucinous components. The degree of WT1 expression was generally weak to moderate (>90% cases) and rarely strong (<10% cases). None of the breast carcinoma subtype unassociated with mucinous component showed WT1 expression.

Original languageEnglish (US)
Pages (from-to)1217-1223
Number of pages7
JournalModern Pathology
Issue number10
StatePublished - Oct 2008
Externally publishedYes


  • Immunotherapy
  • Mucinous and micropapillary breast carcinoma
  • WT1

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'WT1 immunoreactivity in breast carcinoma: Selective expression in pure and mixed mucinous subtypes'. Together they form a unique fingerprint.

Cite this